Diabetic Retinopathy
Conditions
Interventions
Group A:Patients with proliferative diabetic retinopathy (PDR) and tractional retinal detachment (TRD) were treated with intravitreal injection of faricizumab before vitrectomy (PPV)
Group B:Patients with proliferative diabetic retinopathy (PDR) and tractional retinal detachment (TRD) were treated with intravitreal Aflibercept of faricizumab before vitrectomy (PPV)
Sponsors
Foshan Second People's Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients with diabetes aged 20-79; 2. Type 1 or type 2 diabetes; 3. Diagnosed with proliferative diabetic retinopathy (PDR) accompanied by neovascular membranes and/or TRD and/or refractory vitreous hematoma, requiring surgical intervention. 4. Inability to complete panretinal photocoagulation (PRP) due to vitreous hemorrhage (VH) or fibrovascular membranes from neovascularization. 5. Agreement to undergo anti-VEGF therapy prior to vitrectomy for PDR. 6. Participants must voluntarily agree to participate in the study, demonstrate the ability to comply with the study protocol and treatment plan, and commit to attending scheduled follow-up visits.
Exclusion criteria
Exclusion criteria: 1. Patients who have received intravitreal anti-VEGF injections or retinal laser photocoagulation within the past 3 months. 2. Patients who have received intravitreal dexamethasone injections within the past 6 months or intravitreal steroid injections within the past 3 months. 3. Patients with a history of vitrectomy. 4. Diabetic retinopathy (DR) patients with a glycated hemoglobin (HbA1c) level exceeding 12%. 5. Patients with proliferative diabetic retinopathy (PDR) and severe vitreous hemorrhage that precludes observation of the vitreoretinal interface using optical coherence tomography angiography (OCTA). 6. Patients with concurrent severe ocular diseases other than PDR, such as glaucoma, macular degeneration, or other retinal vascular disorders. 7. Patients with active ocular infections or intraocular inflammation. 8. Patients with severe systemic conditions, including uncontrolled diabetes, uncontrolled hypertension, myocardial infarction within the past 6 months, or cerebrovascular accidents. 9. Patients with cognitive impairments, communication difficulties, or other conditions that may hinder adherence to the treatment protocol. 10. Patients with a known history of hypersensitivity to the study drugs, including aflibercept or faricimab or Aflibercept.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aqueous humor cytokines(VEGF,IL-6,TNF-a,CTGF,PEDFMCP-1,ICAM-1,VCAM-1,Ang2);vision acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vitreoretinal junction blood flow;Glycosylated hemoglobin;Glomerular function;Serum creatinine; | — |
Countries
China
Contacts
Public ContactYujuan Huang
Foshan Second People's Hospital
Outcome results
None listed